Hutchmed (China) Ltd - Understand $hcm stock

$HCM Market Cap: $24.31 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.368B

TTM

Gross Margin

41.7%

TTM

Net Earnings

-$71.39M

TTM

Current Assets

$1.048B

Q2 2024

Current Liabilities

$373.3M

Q2 2024

Current Ratio

280.82%

Q2 2024

Total Assets

$1.261B

Q2 2024

Total Liabilities

$520.8M

Q2 2024

Book Value

$740.1M

Q2 2024

Cash

$97.96M

Q2 2024

P/E

-340.6

Nov 29, 2024 EST

Free Cash Flow

-$62.94M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$838.0M	$426.4M	$356.1M	$228.0M	$204.9M	$214.1M	$241.2M	$216.1M	$178.2M	$87.33M	$46.00M	$195.4M	$166.9M	$134.5M	$111.0M	$87.00M	$65.10M	$57.50M	$37.90M	$17.50M	$13.60M
YoY Change	96.52%	19.73%	56.21%	11.27%	-4.31%	-11.23%	11.63%	21.25%	104.06%	89.85%	-76.46%	17.08%	24.09%	21.17%	27.59%	33.64%	13.22%	51.72%	116.57%	28.68%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	$838.0M	$426.4M	$356.1M	$228.0M	$204.9M	$214.1M	$241.2M	$216.1M	$178.2M	$87.33M	$46.00M	$195.4M	$166.9M	$134.5M	$111.0M	$87.00M	$65.10M	$57.50M	$37.90M	$17.50M	$13.60M
Cost Of Revenue	$384.4M	$311.1M	$258.2M	$188.5M	$160.2M	$143.9M	$175.8M	$156.3M	$110.8M	$58.85M	$22.20M	$99.40M	$74.20M	$54.60M	$44.60M	$36.10M	$27.70M	$23.40M	$14.60M	$5.900M	$5.300M
Gross Profit	$453.6M	$115.3M	$97.89M	$39.46M	$44.74M	$70.17M	$65.38M	$59.75M	$67.43M	$28.48M	$23.80M	$96.00M	$92.80M	$79.90M	$66.40M	$50.80M	$37.50M	$34.10M	$23.20M	$11.60M	$8.300M
Gross Profit Margin	54.12%	27.04%	27.49%	17.31%	21.84%	32.77%	27.11%	27.65%	37.84%	32.61%	51.74%	49.13%	55.6%	59.41%	59.82%	58.39%	57.6%	59.3%	61.21%	66.29%	61.03%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Selling, General & Admin	$133.2M	$136.1M	$127.1M	$61.35M	$52.93M	$48.65M	$43.28M	$40.89M	$30.07M	$16.83M	$24.70M	$98.40M	$88.60M	$83.80M	$72.20M	$66.80M	$50.50M	$44.60M	$29.00M	$17.90M	$17.20M
YoY Change	-2.15%	7.06%	107.22%	15.9%	8.82%	12.4%	5.83%	36.01%	78.7%	-31.88%	-74.9%	11.06%	5.73%	16.07%	8.08%	32.28%	13.23%	53.79%	62.01%	4.07%
% of Gross Profit	29.36%	118.04%	129.86%	155.48%	118.32%	69.33%	66.19%	68.44%	44.59%	59.08%	103.78%	102.5%	95.47%	104.88%	108.73%	131.5%	134.67%	130.79%	125.0%	154.31%	207.23%
Research & Development	$302.0M	$386.9M	$299.1M	$174.8M	$138.2M	$114.2M	$75.52M	$65.56M	$47.13M	$29.91M
YoY Change	-21.94%	29.36%	71.13%	26.48%	21.05%	51.16%	15.2%	39.1%	57.55%
% of Gross Profit	66.59%	335.54%	305.52%	442.95%	308.89%	162.7%	115.51%	109.72%	69.9%	105.04%
Depreciation & Amortization	$8.207M	$8.664M	$7.190M	$6.061M	$4.942M	$3.590M	$2.578M	$2.341M	$2.015M	$1.265M	$960.0K	$4.050M	$4.560M	$4.580M	$4.570M	$4.650M	$3.800M	$2.990M	$2.240M	$1.690M	$1.740M
YoY Change	-5.27%	20.5%	18.63%	22.64%	37.66%	39.26%	10.12%	16.18%	59.29%	31.77%	-76.3%	-11.18%	-0.44%	0.22%	-1.72%	22.37%	27.09%	33.48%	32.54%	-2.87%
% of Gross Profit	1.81%	7.51%	7.34%	15.36%	11.05%	5.12%	3.94%	3.92%	2.99%	4.44%	4.03%	4.22%	4.91%	5.73%	6.88%	9.15%	10.13%	8.77%	9.66%	14.57%	20.96%
Operating Expenses	$435.2M	$523.0M	$426.2M	$236.1M	$191.1M	$162.8M	$118.8M	$106.4M	$77.20M	$46.74M	$24.70M	$97.30M	$87.50M	$83.00M	$72.00M	$66.30M	$47.10M	$42.30M	$29.50M	$16.90M	$17.30M
YoY Change	-16.79%	22.71%	80.5%	23.55%	17.39%	37.04%	11.6%	37.89%	65.17%	89.23%	-74.61%	11.2%	5.42%	15.28%	8.6%	40.76%	11.35%	43.39%	74.56%	-2.31%
Operating Profit	$18.38M	-$407.7M	-$328.3M	-$196.7M	-$146.4M	-$92.64M	-$53.42M	-$46.70M	-$9.771M	-$18.26M	-$900.0K	-$1.300M	$5.300M	-$3.100M	-$5.600M	-$15.50M	-$9.600M	-$8.200M	-$6.300M	-$5.300M	-$9.000M
YoY Change	-104.51%	24.18%	66.94%	34.35%	58.01%	73.43%	14.39%	377.91%	-46.49%	1928.78%	-30.77%	-124.53%	-270.97%	-44.64%	-63.87%	61.46%	17.07%	30.16%	18.87%	-41.11%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Interest Expense	$759.0K	$652.0K	$183.4M	$81.50M	$44.61M	$24.30M	$33.42M	$65.11M	$21.62M	$14.22M	$11.10M	$800.0K	-$400.0K	$500.0K	$600.0K	$700.0K	-$300.0K	-$400.0K	-$200.0K	-$200.0K	-$100.0K
YoY Change	16.41%	-99.64%	125.06%	82.67%	83.58%	-27.28%	-48.68%	201.19%	52.0%	28.14%	1287.5%	-300.0%	-180.0%	-16.67%	-14.29%	-333.33%	-25.0%	100.0%	0.0%	100.0%
% of Operating Profit	4.13%												-7.55%
Other Income/Expense, Net	$39.93M	-$2.729M	-$10.22M	$4.485M	$1.367M	$1.017M	$116.0K	$470.0K	$184.0K	-$741.0K	-$100.0K	-$100.0K	-$1.100M	-$700.0K	-$200.0K	-$500.0K	$0.00	$0.00	$400.0K	-$900.0K	$100.0K
YoY Change	-1563.28%	-73.29%	-327.8%	228.09%	34.41%	776.72%	-75.32%	155.43%	-124.83%	641.0%	0.0%	-90.91%	57.14%	250.0%	-60.0%	56294995342131090.0%	0.0%	-100.0%	-144.44%	-1000.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Pretax Income	$58.31M	-$410.4M	-$155.1M	-$110.7M	-$100.4M	-$67.32M	-$19.88M	$18.89M	$12.03M	-$4.777M	$10.10M	$10.90M	$4.800M	-$2.600M	-$5.000M	-$14.80M	-$10.00M	-$8.600M	-$6.200M	-$7.300M	-$13.10M
YoY Change	-114.21%	164.58%	40.14%	10.24%	49.14%	238.59%	-205.27%	56.98%	-351.87%	-147.3%	-7.34%	127.08%	-284.62%	-48.0%	-66.22%	48.0%	16.28%	38.71%	-15.07%	-44.27%
Income Tax	$4.509M	-$283.0K	$11.92M	$4.829M	$3.274M	$3.964M	$3.080M	$4.331M	$1.605M	$1.343M	$1.100M	$4.200M	$3.100M	$2.600M	$2.100M	$1.500M	$800.0K	$0.00	$100.0K	$100.0K	$0.00
% Of Pretax Income	7.73%							22.93%	13.34%		10.89%	38.53%	64.58%
Net Earnings	$100.8M	-$360.8M	-$194.6M	-$125.7M	-$106.0M	-$74.81M	-$26.74M	$11.70M	-$35.01M	-$32.82M	$5.900M	$3.600M	$700.0K	-$6.900M	-$8.700M	-$17.80M	-$17.20M	-$9.600M	-$6.800M	-$6.700M	-$10.00M
YoY Change	-127.93%	85.38%	54.81%	18.59%	41.73%	179.78%	-328.56%	-133.42%	6.68%	-656.2%	63.89%	414.29%	-110.14%	-20.69%	-51.12%	3.49%	79.17%	41.18%	1.49%	-33.0%
Net Earnings / Revenue	12.03%	-84.62%	-54.66%	-55.15%	-51.75%	-34.94%	-11.08%	5.41%	-19.65%	-37.58%	12.83%	1.84%	0.42%	-5.13%	-7.84%	-20.46%	-26.42%	-16.7%	-17.94%	-38.29%	-73.53%
Basic Earnings Per Share	$0.12	-$0.43	-$0.25	-$0.18
Diluted Earnings Per Share	$0.12	-$0.43	-$245.6K	-$180.1K	-$159.3K	-$112.6K	-$43.32K	$19.51K	-$64.05K	-$62.43K	$11.16K	$6.838K	$1.330K	-$13.39K	-$16.98K	-$34.75K	-$33.58K	-$21.00K	-$13.28K	-$13.08K	-$19.53K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Cash & Short-Term Investments	$632.2M	$1.013B	$437.0M	$218.1M	$301.0M	$359.2M	$104.3M	$32.25M	$51.10M	$46.90M	$62.00M	$53.80M	$45.30M	$41.80M	$38.20M	$53.30M	$70.60M	$5.600M	$16.30M	$3.200M
YoY Change	-37.59%	131.79%	100.4%	-27.54%	-16.22%	244.35%	223.48%	-36.89%	8.96%	-24.35%	15.24%	18.76%	8.37%	9.42%	-28.33%	-24.5%	1160.71%	-65.64%	409.38%
Cash & Equivalents	$135.0M	$272.9M	$147.8M	$35.17M	$7.480M	$55.25M	$48.21M	$0.00	$38.90M	$46.90M	$62.00M	$53.80M	$45.30M	$41.80M	$38.20M	$53.30M	$10.10M	$5.600M	$16.30M	$3.200M
Short-Term Investments	$318.9M	$635.4M	$201.4M	$96.91M	$214.9M	$274.0M	$24.89M	$309.0K	$12.20M							$0.00	$60.50M
Other Short-Term Assets	$22.33M	$14.13M	$7.038M	$3.767M		$2.565M	$1.071M	$1.429M	$2.600M	$3.400M	$3.900M	$5.100M	$5.100M	$4.600M	$2.600M	$2.200M	$2.100M	$1.300M	$200.0K	$1.400M
YoY Change	58.05%	100.74%	86.83%			139.5%	-25.05%	-45.04%	-23.53%	-12.82%	-23.53%	0.0%	10.87%	76.92%	18.18%	4.76%	61.54%	550.0%	-85.71%
Inventory	$56.69M	$35.76M	$19.77M	$16.21M	$12.31M	$11.79M	$12.82M	$9.555M	$4.400M	$1.400M	$25.30M	$28.70M	$26.60M	$17.50M	$14.70M	$11.70M	$9.500M	$8.700M	$2.700M	$2.300M
Prepaid Expenses
Receivables	$97.99M	$83.58M	$47.87M	$43.25M	$42.96M	$42.27M	$45.04M	$35.22M	$34.40M	$13.40M	$44.30M	$51.60M	$30.70M	$20.10M	$22.40M	$21.20M	$16.60M	$12.90M	$5.500M	$4.800M
Other Receivables	$30.67M	$65.66M	$19.06M	$35.73M	$14.32M	$16.34M	$4.131M	$11.06M	$1.600M	$2.000M	$15.00M	$1.500M	$0.00	$0.00	$0.00	$0.00	$0.00	$1.500M	$1.200M	$100.0K
Total Short-Term Assets	$839.9M	$1.212B	$530.7M	$317.0M	$370.5M	$432.2M	$167.4M	$89.51M	$94.10M	$67.00M	$150.6M	$140.6M	$107.8M	$83.90M	$77.90M	$88.40M	$98.80M	$30.00M	$26.00M	$11.80M
YoY Change	-30.71%	128.37%	67.41%	-14.44%	-14.27%	158.21%	86.99%	-4.88%	40.45%	-55.51%	7.11%	30.43%	28.49%	7.7%	-11.88%	-10.53%	229.33%	15.38%	120.34%
Property, Plant & Equipment	$84.67M	$53.15M	$32.19M	$27.48M	$17.79M	$15.48M	$11.17M	$9.850M	$8.900M	$6.500M	$33.30M	$29.50M	$29.90M	$30.70M	$32.00M	$25.70M	$22.90M	$22.00M	$13.30M	$11.70M
YoY Change	59.29%	65.15%	17.12%	54.47%	14.92%	38.54%	13.44%	10.67%	36.92%	-80.48%	12.88%	-1.34%	-2.61%	-4.06%	24.51%	12.23%	4.09%	65.41%	13.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$73.78M	$76.48M	$139.5M	$98.94M	$138.3M	$144.2M	$158.5M	$119.8M	$113.0M	$111.4M	$0.00	$0.00	$0.00	$100.0K	$100.0K	$100.0K	$100.0K	$0.00	$700.0K	$800.0K
YoY Change	-3.53%	-45.18%	40.99%	-28.47%	-4.1%	-9.0%	32.36%	5.98%	1.44%				-100.0%	0.0%	0.0%	0.0%		-100.0%	-12.5%
Other Assets	$31.11M	$30.95M	$21.69M	$2.098M	$1.936M	$2.281M	$1.771M	$6.578M	$300.0K	$300.0K	$1.600M	$1.600M	$1.200M	$600.0K	$300.0K	$300.0K	$0.00	$4.100M	$1.800M	$1.900M
YoY Change	0.51%	42.72%	933.7%	8.37%	-15.12%	28.8%	-73.08%	2092.67%	0.0%	-81.25%	0.0%	33.33%	100.0%	100.0%	0.0%		-100.0%	127.78%	-5.26%
Total Long-Term Assets	$189.6M	$160.6M	$193.4M	$148.1M	$161.6M	$165.7M	$175.1M	$140.1M	$124.8M	$118.7M	$58.90M	$54.20M	$52.10M	$43.90M	$40.10M	$39.20M	$34.20M	$32.90M	$19.30M	$19.70M
YoY Change	18.04%	-16.96%	30.57%	-8.34%	-2.51%	-5.32%	24.96%	12.25%	5.14%	101.53%	8.67%	4.03%	18.68%	9.48%	2.3%	14.62%	3.95%	70.47%	-2.03%
Total Assets	$1.029B	$1.373B	$724.1M	$465.1M	$532.1M	$597.9M	$342.4M	$229.6M	$218.9M	$185.7M	$209.5M	$194.8M	$159.9M	$127.8M	$118.0M	$127.6M	$133.0M	$62.90M	$45.30M	$31.50M
YoY Change
Accounts Payable	$71.12M	$41.18M	$31.61M	$23.96M	$25.63M	$24.37M	$35.54M	$24.09M	$20.40M	$4.200M	$18.90M	$16.50M	$10.60M	$8.200M	$5.300M	$5.300M	$3.200M	$3.900M	$1.700M	$3.900M
YoY Change	72.71%	30.26%	31.93%	-6.49%	5.17%	-31.44%	47.55%	18.07%	385.71%	-77.78%	14.55%	55.66%	29.27%	54.72%	0.0%	65.63%	-17.95%	129.41%	-56.41%
Accrued Expenses	$246.0M	$193.5M	$110.7M	$73.54M	$48.45M	$32.76M	$27.25M	$20.96M	$7.200M	$8.400M	$15.70M	$10.90M	$13.70M	$10.10M	$7.100M	$8.700M	$5.100M
YoY Change	27.14%	74.74%	50.6%	51.77%	47.92%	20.23%	29.98%	191.14%	-14.29%	-46.5%	44.04%	-20.44%	35.64%	42.25%	-18.39%	70.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$1.550M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change					-100.0%
Long-Term Debt Due	$0.00	$26.91M	$2.785M	$3.216M	$0.00	$29.99M	$19.96M	$23.08M	$26.30M	$51.50M	$11.20M	$30.00M	$24.50M	$8.100M	$7.600M	$6.600M	$7.100M	$7.400M	$7.200M	$0.00
YoY Change	-100.0%	866.07%	-13.4%		-100.0%	50.26%	-13.52%	-12.25%	-48.93%	359.82%	-62.67%	22.45%	202.47%	6.58%	15.15%	-7.04%	-4.05%	2.78%
Total Short-Term Liabilities	$353.9M	$311.7M	$158.4M	$113.1M	$85.48M	$104.6M	$95.12M	$81.06M	$69.20M	$78.40M	$81.10M	$88.50M	$67.60M	$49.90M	$33.20M	$30.00M	$23.10M	$96.10M	$72.70M	$52.00M
YoY Change	13.55%	96.76%	40.05%	32.31%	-18.28%	9.97%	17.34%	17.14%	-11.73%	-3.33%	-8.36%	30.92%	35.47%	50.3%	10.67%	29.87%	-75.96%	32.19%	39.81%
Long-Term Debt	$23.30M	$7.161M	$32.92M	$29.87M	$26.74M	$0.00	$26.83M	$26.77M	$26.90M	$0.00	$26.90M	$0.00	$0.00	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	225.37%	-78.25%	10.24%	11.7%		-100.0%	0.23%	-0.49%		-100.0%			-100.0%
Other Long-Term Liabilities	$12.66M	$11.56M	$8.784M	$6.093M	$2.809M	$3.914M	$12.43M	$16.08M		$0.00	$15.20M	$27.10M	$22.10M	$1.600M	$0.00
YoY Change	9.5%	31.64%	44.17%	116.91%	-28.23%	-68.51%	-22.68%			-100.0%	-43.91%	22.62%	1281.25%
Total Long-Term Liabilities	$35.96M	$18.72M	$41.71M	$35.96M	$29.55M	$3.914M	$39.26M	$42.85M	$26.90M	$0.00	$42.10M	$27.10M	$22.10M	$1.700M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	92.06%	-55.11%	15.99%	21.7%	654.93%	-90.03%	-8.37%	59.28%		-100.0%	55.35%	22.62%	1200.0%
Total Liabilities	$419.1M	$385.8M	$240.0M	$177.1M	$143.1M	$136.2M	$158.2M	$146.2M	$124.0M	$96.80M	$138.9M	$130.0M	$100.4M	$61.90M	$42.80M	$37.30M	$30.10M	$96.60M	$72.70M	$52.10M
YoY Change	8.63%	60.74%	35.51%	23.75%	5.08%	-13.89%	8.15%	17.94%	28.1%	-30.31%	6.85%	29.48%	62.2%	44.63%	14.75%	23.92%	-68.84%	32.87%	39.54%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	849.7M	847.1M	792.7M	697.9M
Diluted Shares Outstanding	869.2M	847.1M	792.7M	697.9M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $24.314 Billion

About HUTCHMED (China) Ltd

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,988 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Industry: Pharmaceutical Preparations Peers: Regencell Bioscience Holdings Ltd